Regulatory Updates
21 articles on Regulatory Updates, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Drugs for Alcohol Use Disorder: The Future of Addiction Treatment?
GLP-1 receptor agonists, widely known for their efficacy in weight management and type 2 diabetes, are showing remarkable promise in addressing Alcohol Use Disorder (AUD). Emerging research suggests these injectable therapies may fundamentally alter the brain's reward pathways, offering a novel pharmaceutical path for those struggling with heavy drinking.
6 min read
GLP-1 Safety: FDA Action, TrumpRx Access & Weight Loss Drug Risks
Explore the critical safety differences between compounded GLP-1 medications and FDA-approved treatments. Understand the role of new access programs in combating unsafe alternatives.
9 min read
FDA's GLP-1 Compounding Crackdown: What Patients Need to Know
The U.S. Food and Drug Administration (FDA) has announced a significant proposal to restrict the compounding of popular GLP-1 medications, including semaglutide and tirzepatide. This move aims to enhance patient safety and uphold the integrity of approved drug products. Here's a comprehensive look at what this means for individuals managing weight and diabetes.
7 min read
RFK Jr.'s Peptide Policy Could Boost Hims & Hers GLP-1 Shift
Shares of Hims & Hers surged after HHS Secretary RFK Jr. revealed FDA plans to review peptides for compounding under the 503A bulk list. This comes as the telehealth leader evolves its high-margin compounded GLP-1 business toward branded options and new peptide therapies. CEO Andrew Dudum and CMO Dr. Patrick Carroll highlight the potential for regulated, physician-led peptide access.
6 min read
Supplement Makers Push FDA to Allow Peptides and New Ingredients
Dietary supplement makers are pressing the FDA to broaden ingredient criteria, potentially greenlighting peptides and probiotics not traditionally found in food. A key public meeting highlighted industry pleas under RFK Jr.'s health leadership, sparking debates on safety and oversight. Here's what this means for the booming wellness market.
6 min read
Ozempic Goes Generic Worldwide, But Not in U.S. Until 2030
Ozempic, the blockbuster semaglutide drug from Novo Nordisk, is set to go generic in India as early as this weekend, with China, Brazil, Turkey, and South Africa following. This could drop prices to $15 per month, opening access to millions with obesity and diabetes. Meanwhile, U.S. and Europe face delays until 2030 due to patent extensions.
5 min read
Dr. Trehan Warns: Generic GLP-1 Drugs Shouldn't Be OTC
As generic GLP-1 drugs flood the Indian market post-patent expiry, Dr. Naresh Trehan warns they shouldn't be available over-the-counter due to serious side effects. Government advisories stress medical supervision to prevent misuse. Experts like Dr. Gupta and Dr. Bhattacharya highlight risks of self-medication with semaglutide and liraglutide.
6 min read
What Is Orforglipron? New Oral Weight-Loss Pill Trial Results
A groundbreaking phase 3 trial shows orforglipron, a new daily oral weight-loss pill, surpassing oral semaglutide in blood sugar control and weight reduction for type 2 diabetes patients. This small-molecule GLP-1 agonist offers advantages over injectables like Ozempic by eliminating needles and refrigeration needs. However, higher gastrointestinal side effects raise questions about long-term tolerability.
5 min read
GLP-1s Insurance Pricing Challenges: Q&A with Whitney Stidom
High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.
6 min read
India Cracks Down on GLP-1 Drug Misuse Amid Generic Surge
India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.
5 min read
India Steps Up Oversight on GLP-1 Drugs Over Improper Practices
India's drug regulator is cracking down on GLP-1 weight loss drugs due to improper sales and promotions. Inspections across 49 entities revealed violations, leading to notices and potential license cancellations. With semaglutide generics now available post-patent expiry, authorities emphasize prescription-only use by specialists.
4 min read
DCGI Intensifies Crackdown on Unauthorized GLP-1 Weight-Loss Drug Sales
India's DCGI is cracking down harder on the unauthorized sale of GLP-1 weight-loss drugs amid rising generic variants. Inspections at online pharmacies, wholesalers, and clinics aim to prevent misuse that could lead to serious health risks. Patients must seek prescriptions only from qualified endocrinologists or specialists.
4 min read
Govt Cautions Pharma Cos on Surrogate Ads for GLP-1 Drugs
The Indian government has issued a strict advisory cautioning pharmaceutical companies against surrogate advertising to promote GLP-1 drugs, amid fears of consumer misuse. Signed by Drugs Controller General Rajeev Singh Raghuvanshi on March 10, the note prohibits all direct or indirect promotions on any platform. This comes as Ozempic and Wegovy patents near expiry, potentially flooding the market with generics.
6 min read
Aspen Plans Mounjaro Rollout in Sub-Saharan Africa
South Africa's Aspen Pharmacare is accelerating Mounjaro's rollout across sub-Saharan Africa after its explosive success at home, where the GLP-1 market tripled to $133.6 million. With over half the market share and $78.97 million in projected sales, this expansion tests rapid access to advanced weight-loss therapies. Here's how Aspen's KwikPen approval paves the way.
4 min read
FDA Issues Novo Untitled Letter for Apple-Inspired Ozempic Ad
Novo Nordisk has received a second FDA untitled letter in weeks, this time targeting an Ozempic digital ad that parodies Apple's 'Get a Mac' campaign with actors Justin Long and John Hodgman. The regulator cites misleading presentations of Ozempic's indications and unsubstantiated superiority claims over other GLP-1s. Understand the concerns and what it means for patients seeking accurate information on these therapies.
5 min read
RFK Jr. Plans to Unban 14 FDA-Banned Peptides, Tells Joe Rogan
RFK Jr. revealed on the Joe Rogan Experience his intent to lift FDA restrictions on 14 banned peptides from compounding pharmacies. This reversal addresses the late 2023 Category 2 list ban amid safety concerns and black market shifts. Patients and wellness advocates await formal decisions in coming weeks.
5 min read
Sciwind Biosciences $495M Pfizer China Deal for Ecnoglutide GLP-1
Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.
6 min read
Hims & Hers GLP-1 Pill Launch Backfires, Fuels Compounder Crackdown
Hims & Hers aimed to disrupt the GLP-1 market with a cheap oral semaglutide pill, but faced swift FDA backlash and a patent lawsuit from Novo Nordisk. The retreat highlights regulatory risks for compounders as branded supplies stabilize. This analysis reveals challenges in oral GLP-1 production and future paths for telehealth weight loss offerings.
6 min read
Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill
Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.
5 min read
HIMS Shares Sink After FDA Vows Swift Action on Copycat GLP-1 Drugs
Hims & Hers Health's bold launch of a $49-per-month copycat GLP-1 pill to rival Wegovy's $149 price tag backfired spectacularly. FDA Commissioner Marty Makary vowed 'swift action' against such unapproved drugs, sending HIMS shares down 7.5% in premarket trading. This regulatory showdown highlights growing tensions in the GLP-1 market dominated by Novo Nordisk and Eli Lilly.
4 min read
Ozempic Weight Loss: Celebrity Rumors vs. Real Science
When Bollywood star Tamanna Bhatia appeared slimmer, social media buzzed with Ozempic accusations, sparking debates on beauty standards and rapid weight loss. Beyond the rumors, Ozempic (semaglutide) is a powerful GLP-1 drug transforming weight management. This guide dives into the science, risks, and healthier paths forward.
5 min read